News
GHRS
28.22
+11.37%
2.88
GH Research Shareholders Approve Director Slate and 2026 Auditor at June AGM
TipRanks · 1d ago
GH Research shareholders re-elect directors at annual general meeting
PUBT · 1d ago
Weekly Report: what happened at GHRS last week (0615-0619)?
Weekly Report · 5d ago
Weekly Report: what happened at GHRS last week (0608-0612)?
Weekly Report · 06/15 09:23
Weekly Report: what happened at GHRS last week (0601-0605)?
Weekly Report · 06/08 09:22
GH Reports Primary Endpoint Met In Phase 2a For GH001 In Treating Post-Partum Depression
NASDAQ · 06/05 10:26
Psychedelic: Enveric initiates IND-enabling genotoxicity studies of EB-003
TipRanks · 06/04 15:00
GH Research announces publication of Phase 2a results for mebufotenin
TipRanks · 06/04 14:40
GH Research Announces Publication Of Full Results From Its Phase 2a Trial In Postpartum Depression
Benzinga · 06/04 11:18
GH Research says Phase 2a trial shows inhaled GH001 drives rapid remission in postpartum depression patients
PUBT · 06/04 11:04
Weekly Report: what happened at GHRS last week (0525-0529)?
Weekly Report · 06/01 09:23
Compass Pathways: A Psychedelics Story
Seeking Alpha · 05/29 10:40
Weekly Report: what happened at GHRS last week (0518-0522)?
Weekly Report · 05/25 09:24
Psychedelic: Enveric, NRx, Bright Minds report quarterly earnings
TipRanks · 05/21 15:30
GH Research to Present New GH001 Phase 2b Data in Treatment-Resistant Depression at ASCP 2026
TipRanks · 05/21 11:37
GH Research says Phase 2b trial shows GH001 cuts anhedonia scores in TRD
PUBT · 05/21 11:05
GH Research: Rapid Onset And Short Action Change The Treatment Paradigm
Seeking Alpha · 05/20 08:07
GH Research Price Target Cut to $65.00/Share From $70.00 by HC Wainwright & Co.
Dow Jones · 05/19 10:42
GH Research Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 05/19 10:42
HC Wainwright & Co. Maintains Buy on GH Research, Lowers Price Target to $65
Benzinga · 05/19 10:33
More
Webull provides a variety of real-time GHRS stock news. You can receive the latest news about Gh Research Plc through multiple platforms. This information may help you make smarter investment decisions.
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is focusing on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). Its portfolio includes GH001, its proprietary inhalable mebufotenin product candidate and GH002, its proprietary intravenous mebufotenin product candidate. GH001 is delivered via a vaporization device produced by a third party, and the Company is developing a proprietary aerosol delivery device which is in clinical investigation in Europe. GH001 completed two Phase 1 clinical trials in healthy volunteers, a Phase 1/2 trial in TRD and two Phase 2a proof-of-concept trials. GH002 Completed a randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers, and it is developing GH002 within its focus area of psychiatric and neurological disorders.